

POSTER PRESENTATION

Open Access

Anti-plasmodial action of *de-novo*-designed, cationic, lysine-branched, amphipathic, helical peptides

Naveen K Kaushik*, Jyotsna Sharma, Dinkar Sahal

From Challenges in malaria research
Basel, Switzerland. 10-12 October 2012

Background

A lack of vaccine and rampant drug resistance demands new anti-malarials under such circumstances antibiotic peptides may offer a novel approach to tackle the parasite.

Methods

In vitro blood stage anti-plasmodial properties of several *de novo*-designed, chemically synthesized, cationic, amphipathic, helical, antibiotic peptides were examined against *Plasmodium falciparum* using SYBR Green assay. Mechanistic details of anti-plasmodial action were examined by optical/fluorescence microscopy and FACS analysis.

Results

Unlike the monomeric decapeptides {(Ac-GXRKXH-KXWA-NH₂) (X = F, ΔF) (Fm ΔFm IC₅₀ >100 μM)}, the lysine-branched, dimeric versions showed far greater potency {IC₅₀ (μM) Fd 1.5, ΔFd 1.39}. The more helical and proteolytically stable ΔFd was studied for mechanistic details. ΔFq, a K-K₂ dendrimer of ΔFm and (ΔFm)₂ a linear dimer of ΔFm showed IC₅₀ (μM) of 0.25 and 2.4 respectively. The healthy/infected red cell selectivity indices were >35 (ΔFd), >20 (ΔFm)₂ and 10 (ΔFq). FITC-ΔFd showed rapid and selective accumulation in parasitized red cells. Overlaying DAPI and FITC fluorescence suggested that ΔFd binds DNA. Trophozoites and schizonts incubated with ΔFd (2.5 μM) egressed anomalously and Band-3 immunostaining revealed them not to be associated with RBC membrane. Prematurely egressed merozoites from peptide treated cultures were found to be invasion incompetent.

Conclusion

Good selectivity (>35), good resistance index (1.1) and low cytotoxicity indicate the promise of ΔFd against malaria.

Published: 15 October 2012

doi:10.1186/1475-2875-11-S1-P55

Cite this article as: Kaushik et al.: Anti-plasmodial action of *de-novo*-designed, cationic, lysine-branched, amphipathic, helical peptides. *Malaria Journal* 2012 11(Suppl 1):P55.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

